News
Stay up-to-date on our latest news.
Stay up-to-date on our latest news.
Jun 27, 2022
Clover's COVID-19 Vaccine Candidate Demonstrates Strong Cross-Neutralization Against Omicron as a Homologous BoosterJun 13, 2022
Clover Doses First Participants in Phase 3 Trial Evaluating SCB-2019 as a Heterologous COVID-19 Booster Following Prior Vaccination with Inactivated, mRNA or Viral Vector VaccinesJun 05, 2022
Clover Provides Update on 2022 Corporate MilestonesMay 31, 2022
Clover Doses First Participants in Phase 1 Trial with SCB-2020S, a Potentially Broadly Protective Chimeric COVID-19 Vaccine CandidateMay 05, 2022
Clover's Bivalent COVID-19 Vaccine Candidate Demonstrates Broad Neutralization Against Omicron and Other Variants of ConcernApr 27, 2022
Clover Appoints LiongHo Chua as President of Greater ChinaApr 20, 2022
Clover's Efficacy Data in Previously-Infected Individuals is Published in Lancet Infectious DiseaseApr 19, 2022
Clover Presents Updated Durability and Booster Data for COVID-19 Vaccine Candidate at World Vaccine Congress Washington 2022Mar 29, 2022
Clover Reports Full Year 2021 Financial ResultsMar 17, 2022
Clover's COVID-19 Vaccine Candidate Demonstrates Durable High Protection and Immune Responses Against Omicron as a Booster
